Digital PCR (dPCR) is an established method for the fast and reliable identification of significant cancer-related mutations. For liquid biopsy analysis, dPCR assays are a precise, cost-effective, and rapid method for monitoring response and resistance to treatment by testing for relevant cancer-driver and therapy-resistant mutations.
The TaqMan dPCR Liquid Biopsy assays detect and quantify the most common cancer-related mutations (e.g., EGFR, BRAF, KRAS, PIK3CA, JAK2), as well as therapy-resistant mutations (e.g., EGFRT790M). They have been verified and are guaranteed* to perform on the QuantStudio 3D Digital PCR System and other dPCR and droplet digital PCR (ddPCR) instruments, including the Bio-Rad QX-100™ and QX-200™ systems and the Combinati™ Absolute Q™ dPCR System.** To learn more about the Combinati Absolute Q dPCR System, visit www.combinati.com.
White Paper: Minimally invasive, sensitive detection of rare cancer mutations using digital PCR
Liquid biopsies are increasingly being used in the detection of rare mutations for monitoring disease progression and resistance to therapy. In this white paper, learn more about the use of digital PCR as a sensitive technology for the identification of cancer driver and resistance mutations.
Key features of the TaqMan Liquid Biopsy dPCR Assays
Order TaqMan dPCR Liquid Biopsy Assays
Additional liquid biopsy solutions
Targeted next-generation sequencing (NGS) assays
Rare mutation detection assays
Cell-free nucleic acid extraction
For Research Use Only. Not for use in diagnostic procedures.
* Terms and conditions apply. For complete details, go to www.thermofisher.com/taqmanguarantee.
** Bio-Rad and Bio-Rad QX100 and QX200 Droplet Digital PCR Systems are trademarks of Bio-Rad Laboratories, Inc., which is not affiliated with Thermo Fisher Scientific. These statements have not been reviewed or endorsed by Bio-Rad. Combinati and Absolute Q are trademarks of Combinati Inc. TaqMan is a registered trademark of Roche Molecular Systems, Inc., used under license.